If you don't understand one of the words in this article, just double-click it.
A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature
doesn't work in your browser, you can enter the word below:
Encouraging Data From Second Tesamorelin Study for Lipo
by Tim Horn
Treatment with a tesamorelin, a synthetic compound being developed by Theratechnologies in Montreal that sparks the production of natural human growth hormone, resulted in a significant loss of visceral adipose tissue (VAT)—deep belly fat—compared with a placebo in people with lipodystrophy, according to new results reported August 5 at the XVII International AIDS Conference in Mexico City. These data come from the first half of a second confirmatory Phase III clinical trial of the drug and are similar to results seen in the first trial reported in December 2007.
The reported tesamorelin study is a 52-week trial. During the first 26 weeks, 270 patients—about two-thirds of the enrolled study volunteers—received tesamorelin and one-third (126 patients) received a placebo. During the second 26 weeks of the study, those who originally received the placebo will switch to tesamorelin, while those who originally received tesamorelin will either stay on the drug or be switched to placebo.
After the first six months in the study, researcher Steven Grinspoon, MD, of Harvard Medical School in Boston reported that those who received tesamorelin had a 10.9 percent decrease in VAT compared with a 0.6 percent decrease in those who received a placebo. The primary goal of the study was an 8 percent decrease in VAT, indicating that the results are clinically meaningful.
The volume of subcutaneous adipose tissue—fat directly below the skin—increased by an average of 1.1 percent in the tesamorelin group and 0.9 percent in the placebo group.
Patients in the tesamorelin group also had greater improvements in insulin function than those in the placebo group. Most important, there were no significant differences in glucose levels between the two groups after 26 weeks—a noted problem in clinical trials of Serono’s Serostim (recombinant human growth hormone) for lipodystrophy and a potential risk for diabetes.
The frequency of side effects was similar between both groups, with injection-site redness, rash, bruises; joint and extremity pain; and diarrhea being the most common side effects reported.
Please click OK to confirm your comment and confirm you accept our posting rules. Note your message will be reviewed by our staff before going live.
Previous Comments:
comments 1 - 2 (of 2 total)
Dale, Houston, 2008-08-14 12:30:07
When will tesamorelin be approved by the FDA and on the market?
TonyB326, Roselle Park NJ, 2008-08-13 20:20:02
Do you know of any clinical trials for VAT or LIPO in or anround NYC? My insurance company is denying me coverage. My previous Insurance provider was honoring it for years; than my job changed insurance company and the new one AETNA is denying it and my VAT is becoming uncomfortable again, not to mention the body image issues that go along looking at it in the mirror. Any chance that Serostin has a program for people like me who need their product but can't afford it?
